Related Experiment Video
Updated: Aug 19, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
[Antiproliferative effect of tumor necrosis factor-alpha on human glioblastoma cells]
1Department of Neurosurgery, Hokkaido University School of Medicine, Sapporo, Japan.
Abstract:
Although tumor necrosis factor-alpha (TNF) has been applied to early clinical trials for patients with malignant glioma, majority of human glioma cells has been reported to be resistant to TNF cytocidal effect in vitro. This study investigated antiproliferative effect of the TNF associated with induction of differentiation and expression of two distinct TNF receptors on human glioblastoma cell lines. The expression of p55 and p75 TNF receptors on 12 human glioblastoma cell lines was assessed by polymerase chain reaction and flow cytometry. p55 TNF receptor was detected in all cell lines, and only 4 cell lines concomitantly expressed p75 TNF receptor. Twelve human glioblastoma cell lines were treated with low-dose TNF, up to 256 U/ml for 7 days. TNF did not exhibit its cytocidal effect, but showed antiproliferative effects with inhibition of DNA synthesis in majority of cell lines tested. Flow cytometry with the bromodeoxyuridine-propidium iodide dual staining technique demonstrated that this antiproliferative effect of TNF was attributed to accumulation of glioblastoma cells in G0/G1 phase, suppressing the proliferative pathway. Furthermore the TNF stimulation increased glial fibrillary acidic protein and production of bioactive molecules including interleukin(IL)-6, IL-8, granulocyte-macrophage colony stimulating factor, prostaglandin E2 and manganous superoxide dismutase. In conclusion, human glioblastoma cells had p55 TNF receptor as a functional receptor and well responded to low-dose TNF stimulation, but not susceptible TNF cytocydal effect. The effect of TNF on glioblastoma cells appeared to modulate cell differentiation. TNF may be utilized as an agent for a differentiation therapy for human glioblastomas.
Insights
Tumor necrosis factor-alpha (TNF) inhibits glioblastoma cell proliferation and induces differentiation, despite resistance to its direct killing effect. This suggests TNF
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Context:
- Malignant glioma cells often resist tumor necrosis factor-alpha (TNF) cytocidal effects.
- Understanding TNF receptor expression is crucial for glioblastoma treatment strategies.
Purpose:
- To investigate the antiproliferative effects of TNF on human glioblastoma cell lines.
- To examine TNF-induced differentiation and the expression of TNF receptors (p55 and p75) in glioblastoma cells.
Summary:
- Human glioblastoma cells express the p55 TNF receptor and respond to low-dose TNF by inhibiting DNA synthesis and accumulating in the G0/G1 phase.
- TNF stimulation did not cause cell death but promoted differentiation markers like glial fibrillary acidic protein and increased production of cytokines (IL-6, IL-8) and other molecules.
- All 12 tested glioblastoma cell lines expressed the p55 TNF receptor, while only 4 also expressed the p75 TNF receptor.
Impact:
- TNF demonstrates antiproliferative and differentiation-inducing properties in glioblastoma cells, suggesting its potential as a differentiation therapy agent.
- This research highlights the functional role of the p55 TNF receptor in glioblastoma response to TNF.
- Findings contribute to exploring novel therapeutic approaches for glioblastoma beyond conventional cytotoxic treatments.

